NVP-HSP990

NVP-HSP990 is a potent, selective and orally active Hsp90 inhibitor, with IC50 values of 0.6, 0.8, and 8.5 nM for Hsp90α, Hsp90β, and Grp94, respectively.

Product Specifications

CAS Number

[934343-74-5]

Product Name Alternative

HSP-990

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; HSP

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/NVP-HSP990.html

Purity

99.49

Solubility

DMSO : ≥ 33 mg/mL

Smiles

CC1=C2C(C[C@H](C3=C(C4=NC(OC)=CC=C4)C=C(F)C=C3)NC2=O)=NC(N)=N1

Molecular Formula

C20H18FN5O2

Molecular Weight

379.39

Precautions

H302, H315, H319, H335

References & Citations

[1]Menezes DL, et al. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo. Mol Cancer Ther. 2012 Mar;11 (3) :730-9.|[2]McBride CM, et al. Design, structure-activity relationship, and in vivo characterization of the development candidate NVP-HSP990. J Med Chem. 2014 Nov 13;57 (21) :9124-9.|[3]Lamottke B, et al. The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases. Eur J Haematol. 2012 May;88 (5) :406-15.